The KRYSTAL-1 trial was the first-in-human study of the oral KRAS G12C inhibitor adagrasib, which confirmed partial responses in some patients with KRAS G12C–mutant non–small cell lung cancer and colorectal cancer.
USPSTF guidelines have been updated to recommend the use of low-dose computed tomography and expand the criteria for lung cancer screening, aiming to reduce mortality (through more early detection) and ameliorate racial disparities in screening. Despite these updates, screening rates remain low.
Targeted therapies have improved outcomes for patients with advanced non–small cell lung cancer (NSCLC) who harbor mutations in EGFR, ALK, ROS1, RET, NTRK, and KRAS, and those with MET exon 14 skipping mutations; targeted agents represent the standard of care for these patients.
The identification of molecularly defined subsets in non–small cell lung cancer (NSCLC) and the subsequent development of specific targeted therapies (tyrosine kinase inhibitors [TKIs], small molecules, and monoclonal antibodies) have dramatically improved treatment outcomes for patients with these defined molecular alterations.
This site is intended for healthcare professionals in Europe and Japan only.
The selection of ASCO content on this site was made by the ASCO Publication and Education teams. Springer Healthcare selected the experts for interview. All content is made available solely for educational and informational purposes and personal use only.